APPLICATIONS ARE NOW AVAILABLE for the 2019 Industrial Hemp Research Pilot Program. You can access the Grower Application Packet, the Processor/Handler Application Packet, and the University/College Affiliation Application Packet on the Program Page titled "Applications for the Hemp Program" in the right side bar (or scroll further down on mobile devices) or through the green link in the description below. Complete instructions and guidelines for applicants are contained in the application packets. Grower applications are due November 30, 2018 at 4:30 PM Eastern Time.
My mother has dementia/Alzheimers along with a broken knee that they will not repair do to her mental status. She is currently in a nursing home. I firmly believe her mental situation began with the over use of hydrocodone for over 30 years and was acerbated by the trauma of breaking and disconnecting her knee cap. Since weaning her off of her meds (still in progress) we have regained much of her consciousness. I want to try CBD to help in her recovery or to help slow down the disease. I cannot find a dosage recommendation plus the nursing home/doctor does not recommend it. I would need to give it to her when I am there visiting (about 3 - 4 times per week). Is there a recommended dosage for dementia/Alzheimers?
Cannabis has psychoactive and physiological effects when consumed. The immediate desired effects from consuming cannabis include relaxation and euphoria (the "high" or "stoned" feeling), a general alteration of conscious perception, increased awareness of sensation, increased libido and distortions in the perception of time and space. At higher doses, effects can include altered body image, auditory and/or visual illusions, pseudohallucinations and ataxia from selective impairment of polysynaptic reflexes. In some cases, cannabis can lead to dissociative states such as depersonalization and derealization.
Jump up ^ Hayakawa K, Mishima K, Nozako M, Ogata A, Hazekawa M, Liu AX, Fujioka M, Abe K, Hasebe N, Egashira N, Iwasaki K, Fujiwara M (March 2007). "Repeated treatment with cannabidiol but not Delta9-tetrahydrocannabinol has a neuroprotective effect without the development of tolerance". Neuropharmacology. 52 (4): 1079–87. doi:10.1016/j.neuropharm.2006.11.005. PMID 17320118.
In an in vivo model using severe combined immunodeficient mice, subcutaneous tumors were generated by inoculating the animals with cells from human non-small cell lung carcinoma cell lines. Tumor growth was inhibited by 60% in THC-treated mice compared with vehicle-treated control mice. Tumor specimens revealed that THC had antiangiogenic and antiproliferative effects. However, research with immunocompetent murine tumor models has demonstrated immunosuppression and enhanced tumor growth in mice treated with THC.[24,25]
Among the company’s many offerings is Real Scientific Hemp Oil, which it sells through its subsidiary HempMedsPx, also based in Poway. On its web site, HempMedsPx describes how its hemp “is grown in northern European microclimates, without the use of any pesticides, herbicides or chemical fertilizers.” The company promises that it “continuously scrutinizes and improves the processes to meet all regulations and exceeds quality standards.”
Strasser F, Luftner D, Possinger K, et al.: Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. J Clin Oncol 24 (21): 3394-400, 2006. [PUBMED Abstract]
The good news is that most of the official research done on CBD oil has shown that there are very few negative side effects from using it. However, CBD is not without some side effects. Most notably, in the clinical studies for epilepsy, sedation was one of the more common side effects. Decreased appetite and diarrhea were also seen in some patients. Depending on what other medicines they are taking, certain patients may need to have periodic blood tests to check on liver function.
Cohen has found that chronic conditions including autoimmune diseases and pain syndromes can be helped with a 6-mg under-the-tongue tincture (the fastest delivery system) or a 25-mg capsule taken twice a day. Dosages for topical products like lotions are especially hard to determine—there’s no clarity on how much CBD gets into the system through the skin.
The first step to finding your correct CBD dosage is getting as much information as you can about the product you’re using. What is the concentration of CBD? Are there third-party lab tests that can confirm that? The CBD industry is still mainly a grassroots therapeutic movement, and as such, largely unregulated. Concentration and purity levels can differ greatly depending on the manufacturing process.
Canabidol™ Oral Capsules deliver 100% Cannabis Sativa L. from specifically bred industrial hemp plants containing high potency Cannabidiol. Each CBD capsule contains all the Cannabinoids, terpenoids, essential oils and all the other compounds of the cannabis plant. A packet of 30 capsules contains 15,000mg of Cannabis Sativa L. and 300mg of CBD (Cannabidiol) Each capsule contains 500mg of Cannabis Sativa L. and 10mg of the active ingredient CBD
In the United States, non-FDA approved CBD products are classified as Schedule I drugs under the Controlled Substances Act. This means that production, distribution, and possession of non-FDA approved CBD products is illegal under federal law. In addition, in 2016 the Drug Enforcement Administration added "marijuana extracts" to the list of Schedule I drugs, which it defined as "an extract containing one or more cannabinoids that has been derived from any plant of the genus Cannabis, other than the separated resin (whether crude or purified) obtained from the plant." Previously, CBD had simply been considered "marijuana", which is a Schedule I drug.
In 1951, Congress passed the Boggs Act, which for the first time included Cannabis with narcotic drugs. In 1970, with the passage of the Controlled Substances Act, marijuana was classified by Congress as a Schedule I drug. Drugs in Schedule I are distinguished as having no currently accepted medicinal use in the United States. Other Schedule I substances include heroin, LSD, mescaline, and methaqualone.
Although CBD oils aren’t regulated by the FDA, purchasing products stateside from one of the nine states where recreational and medical cannabis use is legal will likely result in a higher-quality product than buying one made with hemp-derived CBD oil imported from abroad, says Martin Lee, director of Project CBD, a nonprofit that promotes medical research into CBD.
It has been contended that hemp is notably superior to most crops in terms of biomass production, but van der Werf (1994b) noted that the annual dry matter yield of hemp (rarely approaching 20 t/ha) is not exceptional compared to maize, beet, or potato. Nevertheless, hemp has been rated on a variety of criteria as one of the best crops available to produce energy in Europe (Biewinga and van der Bijl 1996). Hemp, especially the hurds, can be burned as is or processed into charcoal, methanol, methane, or gasoline through pyrolysis (destructive distillation). As with maize, hemp can also be used to create ethanol. However, hemp for such biomass purposes is a doubtful venture in North America. Conversion of hemp biomass into fuel or alcohol is impractical on this continent, where there are abundant supplies of wood, and energy can be produced relatively cheaply from a variety of sources. Mallik et al. (1990) studied the possibility of using hemp for “biogas” (i.e. methane) production, and concluded that it was unsuitable for this purpose. Pinfold Consulting (1998) concluded that while there may be some potential for hemp biomass fuel near areas where hemp is cultivated, “a fuel ethanol industry is not expected to develop based on hemp.”
Cannabis has long had an image problem, because of the extremely widespread use of “narcotic” cultivars as illegal intoxicants. The US Drug Enforcement Administration has the mandate of eliminating illicit and wild marijuana, which it does very well (Fig. 54–56). Those interested in establishing and developing legitimate industries based on fiber and oilseed applications have had to struggle against considerable opposition from many in the political and law enforcement arenas. The United States National Institute on Drug Abuse (NIDA) information web site on marijuana, which reflects a negative view of cannabis, is at www.nida.nih.gov/DrugPages/Marijuana.html, and reflects several basic fears: (1) growing Cannabis plants makes law enforcement more difficult, because of the need to ensure that all plants cultivated are legitimate; (2) utilization of legitimate Cannabis products makes it much more difficult to maintain the image of the illegitimate products as dangerous; (3) many in the movements backing development of hemp are doing so as a subterfuge to promote legalization of recreational use of marijuana; and (4) THC (and perhaps other constituents) in Cannabis are so harmful that their presence in any amount in any material (food, medicine or even fiber product) represents a health hazard that is best dealt with by a total proscription.
As a result of intensive selection in cultivation, Cannabis exhibits many sexual phenotypes that can be described in terms of the ratio of female to male flowers occurring in the individual, or typical in the cultivar. Dioecious varieties are preferred for drug production, where the female flowers are used. Dioecious varieties are also preferred for textile fiber production, whereas monoecious varieties are preferred for pulp and paper production. It has been suggested that the presence of monoecy can be used to differentiate licit crops of monoecious hemp from illicit drug crops. However, sativa strains often produce monoecious individuals, probably as a result of inbreeding.
^ Jump up to: a b c Whiting, PF; Wolff, RF; Deshpande, S; Di Nisio, M; Duffy, S; Hernandez, AV; Keurentjes, JC; Lang, S; Misso, K; Ryder, S; Schmidlkofer, S; Westwood, M; Kleijnen, J (23 June 2015). "Cannabinoids for Medical Use: A Systematic Review and Meta-analysis" (PDF). JAMA. 313 (24): 2456–2473. doi:10.1001/jama.2015.6358. hdl:10757/558499. PMID 26103030.
Hemp has at times in the past been grown simply for its ornamental value. The short, strongly-branched cultivar ‘Panorama’ (Fig. 43) bred by Iván Bósca, the dean of the world’s living hemp breeders, was commercialized in Hungary in the 1980s, and has been said to be the only ornamental hemp cultivar available. It has had limited success, of course, because there are very few circumstances that permit private gardeners can grow Cannabis as an ornamental today. By contrast, beautiful ornamental cultivars of opium poppy are widely cultivated in home gardens across North America, despite their absolute illegality and the potentially draconian penalties that could be imposed. Doubtless in the unlikely event that it became possible, many would grow hemp as an ornamental.
Former President Barack Obama defined industrial hemp as a distinct crop from marijuana in the 2014 U.S. Farm Bill, authorizing higher education institutions and state agricultural departments to give the green light to "regulate and conduct research and pilot programs." But with its classification as a Schedule 1 drug still in effect, the path toward cultivating industrial hemp hasn't been an easy one.
A panellized system of hemp-lime panels for use in building construction is currently under test in a European Union-funded research collaboration led by the University of Bath. The panels are being designed to assure high-quality construction, rapid on-site erection, optimal hygrothermal performance from day one, and energy- and resource-efficient buildings. The 36-month-long work programme aims to refine product and manufacturing protocols, produce data for certification and marketing, warranty, insurance cover, and availability of finance. It also includes the development of markets in Britain, France, and Spain.